Boston Sci Q2 Revenue Up 23%

Boston Scientific (NYSE:BSX), a leading medical device maker known for its heart and surgical products, released second-quarter results on July 23, 2025. Revenue reached $5.06 billion for Q2 2025, beating analyst estimates of $4.89 billion. Adjusted EPS finished at $0.75 for Q2 2025 compared to a consensus estimate of $0.73. Driven by high performance in Cardiovascular devices, the period marked another quarter of strong execution, but management noted some lag in organic net sales growth in its MedSurg area and called attention to coming headwinds tied to $200 million in expected tariffs for the remainder of fiscal 2025.Source: Boston Scientific. Note: Analysts' consensus estimates for the quarter provided by FactSet. The company specializes in developing and manufacturing medical devices that help diagnose and treat a variety of health conditions. Its two main operating groups are Cardiovascular, which includes devices for heart rhythm disorders, coronary interventions, and heart failure, and MedSurg, which makes products for surgery, urology, and pain management. Well-known offerings include the WATCHMAN FLX left atrial appendage closure device, used to reduce stroke risk in patients with irregular heartbeats, and FARAPULSE, a pulsed field ablation catheter platform for treating atrial fibrillation.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool